NGLFINE vs SHILPAMED: Stock Comparison
NGL Fine-Chem Limited vs Shilpa Medicare Limited
Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings
Shilpa Medicare Limited is the larger company by market capitalisation. NGL Fine-Chem Limited shows a lower P/E, a higher ROE and faster revenue growth, while Shilpa Medicare Limited shows a higher dividend yield, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of NGL Fine-Chem Limited and Shilpa Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Live Price | ₹3,260 | ₹615.6 |
| Day Change | 0.7% | -3.81% |
| Volume | 5,595 | 4.89 L |
| 52-Week High | ₹3,329 | ₹860 |
| 52-Week Low | ₹1,175.5 | ₹259.5 |
| Distance from 52W High | -2.07% | -28.42% |
Valuation
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Market Cap | ₹2,015 Cr | ₹12,013 Cr |
| P/E Ratio | 41.23x | 51.29x |
| P/B Ratio | 6.03x | 4.82x |
| EPS | ₹78.04 | ₹12.44 |
| Book Value | ₹532.95 | ₹132.46 |
| Dividend Yield | 0.05% | 0.08% |
Growth
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Revenue Growth (TTM YoY) | 57.2% | 31.5% |
| EPS Growth (TTM YoY) | 1,539.8% | 644.6% |
| Qtr Sales Growth | 57.1% | 32.1% |
| Qtr Profit Growth | 2,398% | 148% |
Profitability & Leverage
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| ROE | 15.7% | 9.4% |
| ROCE | 17% | 11% |
| Net Margin | 9.59% | 15.82% |
| Operating Margin | 14.5% | 28.2% |
| Debt to Equity | 0.33x | 0.25x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Promoter Holding | 72.74% | 40.13% |
| FII Holding | 0.03%▲ 0.03 pp | 11.38%▲ 0.3 pp |
| DII Holding | 0% | 8.05%▼ 0.53 pp |
| Public Holding | 27.24%▼ 0.02 pp | 40.43%▲ 0.22 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NGL Fine-Chem Limited and Shilpa Medicare Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.